These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

568 related items for PubMed ID: 8628494

  • 1. Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.
    Tedroff J, Pedersen M, Aquilonius SM, Hartvig P, Jacobsson G, Långström B.
    Neurology; 1996 May; 46(5):1430-6. PubMed ID: 8628494
    [Abstract] [Full Text] [Related]

  • 2. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride.
    Antonini A, Schwarz J, Oertel WH, Pogarell O, Leenders KL.
    Mov Disord; 1997 Jan; 12(1):33-8. PubMed ID: 8990051
    [Abstract] [Full Text] [Related]

  • 3. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.
    Antonini A, Vontobel P, Psylla M, Günther I, Maguire PR, Missimer J, Leenders KL.
    Arch Neurol; 1995 Dec; 52(12):1183-90. PubMed ID: 7492293
    [Abstract] [Full Text] [Related]

  • 4. Attenuation of fluctuating striatal synaptic dopamine levels in patients with Parkinson disease in response to subthalamic nucleus stimulation: a positron emission tomography study.
    Nimura T, Yamaguchi K, Ando T, Shibuya S, Oikawa T, Nakagawa A, Shirane R, Itoh M, Tominaga T.
    J Neurosurg; 2005 Dec; 103(6):968-73. PubMed ID: 16381182
    [Abstract] [Full Text] [Related]

  • 5. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.
    Brooks DJ, Ibanez V, Sawle GV, Playford ED, Quinn N, Mathias CJ, Lees AJ, Marsden CD, Bannister R, Frackowiak RS.
    Ann Neurol; 1992 Feb; 31(2):184-92. PubMed ID: 1575457
    [Abstract] [Full Text] [Related]

  • 6. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias.
    de la Fuente-Fernández R, Sossi V, Huang Z, Furtado S, Lu JQ, Calne DB, Ruth TJ, Stoessl AJ.
    Brain; 2004 Dec; 127(Pt 12):2747-54. PubMed ID: 15329355
    [Abstract] [Full Text] [Related]

  • 7. [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: Influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors.
    Antonini A, Schwarz J, Oertel WH, Beer HF, Madeja UD, Leenders KL.
    Neurology; 1994 Jul; 44(7):1325-9. PubMed ID: 8035939
    [Abstract] [Full Text] [Related]

  • 8. Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride.
    Rinne JO, Laihinen A, Ruottinen H, Ruotsalainen U, Någren K, Lehikoinen P, Oikonen V, Rinne UK.
    J Neurol Sci; 1995 Oct; 132(2):156-61. PubMed ID: 8543941
    [Abstract] [Full Text] [Related]

  • 9. Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: a double-tracer positron emission tomography study.
    Ouchi Y, Kanno T, Okada H, Yoshikawa E, Futatsubashi M, Nobezawa S, Torizuka T, Sakamoto M.
    Ann Neurol; 1999 Nov; 46(5):723-31. PubMed ID: 10553989
    [Abstract] [Full Text] [Related]

  • 10. Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients.
    Politis M, Wu K, Loane C, Brooks DJ, Kiferle L, Turkheimer FE, Bain P, Molloy S, Piccini P.
    J Clin Invest; 2014 Mar; 124(3):1340-9. PubMed ID: 24531549
    [Abstract] [Full Text] [Related]

  • 11. Chronic exposure to dopamine agonists affects the integrity of striatal D2 receptors in Parkinson's patients.
    Politis M, Wilson H, Wu K, Brooks DJ, Piccini P.
    Neuroimage Clin; 2017 Mar; 16():455-460. PubMed ID: 28879087
    [Abstract] [Full Text] [Related]

  • 12. D2 receptor binding in dopa-responsive dystonia.
    Künig G, Leenders KL, Antonini A, Vontobel P, Weindl A, Meinck HM.
    Ann Neurol; 1998 Nov; 44(5):758-62. PubMed ID: 9818931
    [Abstract] [Full Text] [Related]

  • 13. Asymmetrical pre-synaptic and post-synpatic changes in the striatal dopamine projection in dopa naïve parkinsonism. Diagnostic implications of the D2 receptor status.
    Sawle GV, Playford ED, Brooks DJ, Quinn N, Frackowiak RS.
    Brain; 1993 Aug; 116 ( Pt 4)():853-67. PubMed ID: 8353712
    [Abstract] [Full Text] [Related]

  • 14. Modification of dopamine D2 receptor activity by pergolide in Parkinson's disease: an in vivo study by PET.
    Linazasoro G, Obeso JA, Gómez JC, Martínez M, Antonini A, Leenders KL.
    Clin Neuropharmacol; 1999 Aug; 22(5):277-80. PubMed ID: 10516878
    [Abstract] [Full Text] [Related]

  • 15. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.
    Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, Lang AE, Rascol O, Ribeiro MJ, Remy P, Poewe WH, Hauser RA, Brooks DJ, REAL-PET Study Group.
    Ann Neurol; 2003 Jul; 54(1):93-101. PubMed ID: 12838524
    [Abstract] [Full Text] [Related]

  • 16. Upregulation of putaminal dopamine D2 receptors in early Parkinson's disease: a comparative PET study with [11C] raclopride and [11C]N-methylspiperone.
    Kaasinen V, Ruottinen HM, Någren K, Lehikoinen P, Oikonen V, Rinne JO.
    J Nucl Med; 2000 Jan; 41(1):65-70. PubMed ID: 10647606
    [Abstract] [Full Text] [Related]

  • 17. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease.
    Antonini A, Leenders KL, Vontobel P, Maguire RP, Missimer J, Psylla M, Günther I.
    Brain; 1997 Dec; 120 ( Pt 12)():2187-95. PubMed ID: 9448574
    [Abstract] [Full Text] [Related]

  • 18. Levodopa pharmacokinetic-pharmacodynamic modeling and 6-[18F]levodopa positron emission tomography in patients with Parkinson's disease.
    Dietz M, Harder S, Graff J, Künig G, Vontobel P, Leenders KL, Baas H.
    Clin Pharmacol Ther; 2001 Jul; 70(1):33-41. PubMed ID: 11452242
    [Abstract] [Full Text] [Related]

  • 19. Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study.
    Pavese N, Evans AH, Tai YF, Hotton G, Brooks DJ, Lees AJ, Piccini P.
    Neurology; 2006 Nov 14; 67(9):1612-7. PubMed ID: 17101892
    [Abstract] [Full Text] [Related]

  • 20. Dopamine release during sequential finger movements in health and Parkinson's disease: a PET study.
    Goerendt IK, Messa C, Lawrence AD, Grasby PM, Piccini P, Brooks DJ, PET study.
    Brain; 2003 Feb 14; 126(Pt 2):312-25. PubMed ID: 12538400
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.